New treatment options for lupus – a focus on belimumab

Belimumab is the first biologic approved for patients with systemic lupus erythematosus (SLE). Belimumab is the first of a new class of drug targeting B cell-stimulating factors or their receptors to reach the market. Its target, BLyS, also known as BAFF (B cell-activating factor from the tumor necrosis factor family), is a type II transmembrane protein that exists in both membrane-bound and soluble forms. Additionally to a robust rational from murine experiments conducted in lupus prone mice, BLyS circulating levels are increased in SLE patients. After the negative results of a Phase II trial, two Phase III trials met their primary endpoints. Some SLE patients are still refractory to the standard options of care or necessitate prolonged high-dose corticotherapy and/or long-term immunosuppressive regimens. However, some experts still feel that the effect of this biologic might not be clinically relevant and blame the use of the new systemic lupus response index as well as the discrepancies between both trials and the noninclusion of the severe form of the disease as nephritis. In this review, we aim to discuss the characteristics of belimumab, critically evaluate the different steps of its development, and consider its future place in the arsenal against SLE, taking into account the patients’ perspectives

Interactions ville-hôpital (impact des prescriptions hospitalières des incretinomimetiques dans la prise en charge du diabète de type 2)

AIX-MARSEILLE2-BU Pharmacie (130552105) / SudocSudocFranceF

Le pharmacien et la maladie d'Alzheimer

AIX-MARSEILLE2-BU Pharmacie (130552105) / SudocSudocFranceF

Grossesse et diabète

AIX-MARSEILLE2-BU Pharmacie (130552105) / SudocSudocFranceF

Etude de l'utilisation des antipsychotiques atypiques dans l'urgence psychiatrique

AIX-MARSEILLE2-BU Pharmacie (130552105) / SudocSudocFranceF

L' acné (conseils à l'officine)

AIX-MARSEILLE2-BU Pharmacie (130552105) / SudocSudocFranceF

Fingolimod, premier traitement oral de la sclérose en plaques (quels changements pour les patients ?)

AIX-MARSEILLE2-BU Pharmacie (130552105) / SudocSudocFranceF

Enfuvirtide dans la prise en charge thérapeutique de l'infection à VIH ( place de l'enfuvirtide au sein de l'arsenal thérapeutique. Facteurs limitant le choix de son utilisation. Enjeux de santé publique )

AIX-MARSEILLE2-BU Pharmacie (130552105) / SudocSudocFranceF

Impact des facteurs prédictifs d'efficacité et de tolérance des trithérapies anti-VHC en pratique clinique

AIX-MARSEILLE2-BU Pharmacie (130552105) / SudocSudocFranceF

Dispensation hospitalière des antirétroviraux aux patients en ambulatoire (enquête à la pharmacie du C.H.U. Conception)

AIX-MARSEILLE2-BU Pharmacie (130552105) / SudocSudocFranceF